Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review

Mannelli, Giuditta; Comini, Lara Valentina; Sacchetto, Andrea; Santoro, Roberto; Spinelli, Giuseppe; Bonomo, Pierluigi; Desideri, Isacco; Bossi, Paolo; Orlandi, Ester; Alderotti, Giammarco; Franchi, Alessandro; Palomba, Annarita; Eccher, Albino; Marchioni, Daniele; Nocini, Riccardo; Piazza, Cesare; Molteni, Gabriele

doi:10.1002/hed.27062

Cited by 6 publications

(1 citation statement)

References 120 publications

(387 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This can be combined with concurrent/adjuvant radiotherapy and/or chemotherapy, depending on lymph node involvement, recurrence, or metastasis of the SGM. The treatment strategies for localized SGMs have extensively been described in other reviews and will not be covered in the current review [ 26 , 27 , 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?

Cleymaet

Vermassen

Coopman

et al. 2022

IJMS

View full text Add to dashboard Cite

Salivary gland malignancies (SGMs) account for less than 5% of new diagnoses in head and neck tumors. If feasible, surgery is the preferred treatment modality. Nevertheless, some malignancies have a tendency of recurrence, with possible distant metastasis. Alternative treatment strategies, such as primary radiation or chemotherapeutics, often present low response rates. As a result, there is an unmet need for novel therapeutic approaches. Nowadays, target-based therapies (e.g., small inhibitors and immunotherapy) are used by the medical oncologist for possible treatment of advanced SGMs. Based on recent published trials, some novel treatments may provide additional disease control for some patients. However, sample sizes are small, the general findings are unsatisfactory, and a lot of uncertainties remain to be elucidated. Nevertheless, research shows that patients do not benefit from blind administration of systemic treatments and therefore a more personalized approach is highly needed. The aim of this review paper is to summarize the most recent advances in the biological understanding and molecular pathways of salivary gland cancers the association of these pathways with the current treatments used and their implications for more personalized targeted-based therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?

Cleymaet

Vermassen

Coopman

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review

et al. 2022

View full text Add to dashboard Cite

Recurrent salivary gland carcinomas (RSCs) are poorly characterized and their clinical features and treatment options have not yet been fully described. The goal of this study was to analyze the therapeutic strategies and oncological outcomes of RSC patients through a literature review analysis. This systematic review was performed according to the PRISMA statements. Inclusion criteria for the systematic review were based on the population, intervention, comparison, and outcomes according to (PICO) framework. Two thousand seven hundred and four records were selected and 1817 recurrences were studied. Three hundred and sixty-five patients underwent salvage surgery (20.1%) and their

show abstract

Recurrence after primary salivary gland carcinoma: Frequency, survival, and risk factors

Nachtsheim,

Jansen,

Shabli

et al. 2024

Head & Neck

View full text Add to dashboard Cite

BackgroundPrimary salivary gland carcinomas (SGC) are rare neoplasms that present therapeutic challenges especially in recurrent tumors. The aim of this study was to investigate the incidence and distribution of tumor recurrence, associated risk factors, and survival.MethodsThis analysis includes data from 318 patients treated for SGC between 1992 and 2020. Survival analysis was performed using the Kaplan–Meier method. Univariate and multivariate analyses were used to identify risk factors associated with recurrence.Results21.7% of the patients developed recurrent disease after a mean of 38.2 months. In multivariate analysis, positive‐resection margins, vascular invasion, and tumor localization in the submandibular gland and small salivary glands were independent factors for recurrence. The 5‐year overall survival was 67%, the 5‐year disease‐free survival was 54%.ConclusionTumor recurrence in SGC occurred in one out of five patients. In highly aggressive entities and patients with risk factors, treatment intensification should be considered.

show abstract

Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review

Cited by 6 publications

References 120 publications

The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?

The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?

Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review

Recurrence after primary salivary gland carcinoma: Frequency, survival, and risk factors

Contact Info

Product

Resources

About